Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The transforming growth factor beta-1 (TGFβ-1 -509 C/T) polymorphism was inversely associated with having an oral SCCA among persons homozygous for the recessive variant (ORcrude = 0.27; 95% CI 0.09-0.79).
|
24278120 |
2013 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma.
|
17990985 |
2007 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer.
|
19260117 |
2009 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population.
|
17680270 |
2008 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical Study of TGF-β1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma: Correlations Between Clinicopathologic Factors and Overall Survival.
|
26990749 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Aberrant expression of Smad4, a TGF-beta signaling molecule, in oral squamous cell carcinoma.
|
17023741 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant majority of a new series of human SCC cell lines were found to be as sensitive as primary human epidermal keratinocytes to TGF-beta 1 growth inhibition.
|
8891333 |
1996 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A study in this issue of Cancer Cell shows that mice with a targeted knockout of the type II TGFbeta receptor in stratified epithelia specifically develop spontaneous squamous cell carcinomas in the anogenital region, but not in the skin.
|
17936552 |
2007 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix.
|
15033492 |
2004 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We incubated the p16-positive CERV196 and p16-negative HNSCC22B SCC cell lines with EGF and EGF/TGFβ1 (10 ng/ml) and detected E-cadherin, vimentin and β-catenin by immunocytochemistry and enzyme-linked immunosorbent assay after 5, 24 and 96 h.
|
25503133 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Use of a TGFbeta type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFbeta signaling in tumor promotion and progression.
|
20852150 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway.
|
17217620 |
2006 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that NK cells in NSCLC act as proangiogenic cells, particularly evident for SCC and in part mediated by TGFβ(1).
|
23441128 |
2013 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma.
|
18418730 |
2009 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A panel of 45 formalin-fixed and paraffin-embedded NSCLC specimens showed positive immunostaining for TGF-beta 1, TGF-beta RI, and TGF-beta RII, with reduced TGF-beta RII in poorly differentiated adenocarcinomas and squamous cell carcinomas and some moderately differentiated adenocarcinomas.
|
11195465 |
2000 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the role of TGF-β1 on epithelial mesenchymal transition (EMT) and invasion in oral squamous cell carcinoma cell line Tca8113.
|
28537671 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Inhibition of TGF-beta1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases.
|
19082463 |
2009 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TGF-β1/TβRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages.
|
29462614 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma.
|
14712482 |
2004 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.
|
24954139 |
2014 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of TGF‑β1 and SMAD4 proteins was elevated in cervical squamous carcinoma and cervical adenocarcinoma tissues.
|
27748903 |
2016 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TGF-beta 1 and EGF regulation of PTH-rP gene expression in squamous cell carcinomas of gynecologic origin is unique for each cell line studied and different from that in human lung carcinoid cells.
|
8111720 |
1994 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
The expression levels of TGF-beta1 and its type I and type II receptors (TbetaRI and TbetaRII) were assessed by immunohistochemical and Western blot analyses in 22 oral squamous cell carcinoma lesions, in their normal adjacent mucosa and in the squamous carcinoma cell lines FaDu and CAL27.
|
18202754 |
2008 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TGF-β1 protein and its receptor I (TGF-βR1) were overexpressed in urine samples in malignant group compared with chronic cystitis and in SQCC group compared with TCC group.
|
21429769 |
2013 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Conversely, increased TGF-β1 and activated TGF-βRI and Smad3 have all been shown to have tumor-promoting effects in experimental systems of human and mouse SCCs.
|
29206939 |
2018 |